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Abstract
Purpose International reference data for the SF-36 health
survey (version 1) are presented based on a sample of 5508
adult patients with ischemic heart disease.
Methods Patients with angina, myocardial infarction and
ischemic heart failure completed the SF-36. Data were
analyzed by diagnosis, gender, age, region and country
within region and presented as mean ± standard deviation
(SD), minimum, maximum, 25th, 50th and 75th percentile
of the physical (PCS) and mental component summary
(MCS) measures.
Results Mean PCS scores were reported as being more
than one SD below the normal range (standardized mean of
50 ± 10) by more than half of the patient subgroups (59 %)
with all of the mean MCS scores falling within the normal
range. Patients with angina and patients with ischemic
heart failure reported the poorest mean PCS scores with
both diagnoses reporting scores more than one SD below
the standardized mean. Females, older patients (especially
[70 years) and patients from Eastern Europe reported
significantly worse mean PCS scores than male, younger
and non-Eastern European patients. The cardiac diagnosis
had no effect on the mean MCS scores; however, females,
younger patients (especially\51 years) and patients from
Eastern Europe reported significantly worse mean MCS
scores than male, older and non-Eastern European patients.
Conclusions These international reference SF-36 values
for patients with IHD are useful for clinicians, researchers
and health-policy makers when developing improved
health services.
Keywords SF-36  Reference data  Ischemic heart
disease  Angina  Myocardial infarction  Heart failure
Introduction
Health-related quality of life (HRQL), as an integral aspect
of subjective patient-reported health status, has become an
increasingly important health care outcome measure,
especially in patients with chronic diseases, for example,
cardiovascular disease [1–3]. In 2012, cardiovascular dis-
eases were the number one cause of death globally with
about 17.5 million people dying of cardiovascular diseases,
or 31 % of all global deaths; of these deaths, approximately
7.4 million (42 %) were due to ischemic heart disease
(IHD) [4]. Patient-reported health status, including HRQL,
is predictive of mortality, cardiovascular events, hospital-
ization and costs of care in patients with cardiovascular
disease; despite this, instruments to assess patient-reported
health status are underused in clinical practice [1, 2].
Attributes and criteria for HRQL instruments are
important as quality indicators. Key attributes of HRQL
instruments include the conceptual and measurement
model, reliability, validity, language adaptations and
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interpretability [5]. The key to the interpretation of HRQL
is having reference data. Without such data, it is difficult
for the user to assess the meaning of the scores because
benchmark values are missing. For example, reference data
allow a determination of whether group or individual
HRQL scores and standard deviations are below, similar to,
or above those of a reference group thus placing them into
a context; furthermore, comparing percentiles and mini-
mum/maximum values in a study sample can provide
useful information on the distribution of HRQL scores [6].
A number of instruments have been developed to quantify
HRQL, and some HRQL manuals offer population norms
and distributions relating to gender, age or disease [7, 8]
while various studies have provided within-country [9–11]
and between-country [12, 13] HRQL comparative data.
The Short Form-36 health survey (SF-36) [8, 12, 13] is
arguably one of the most widely used generic health-re-
lated quality of life measures in the general population and
also in patients with IHD [12–19].
The International Quality of Life Assessment (IQOLA)
Project [12, 13] was a comprehensive project to translate, adapt
and validate the SF-36 internationally in patients with chronic
disease. Patients with congestive heart failure reported the
second lowest SF-36 physical health, while the ‘‘effect of
ischemic heart disease on a number of physical health scales
was noteworthy.’’ TheEuroAspire III study [20] used theSF-12
in patientswith IHD,where lowerHRQL estimateswere found
in women, older patients and patients from Eastern European
countries. Soto et al. [15] also reported lower physical health
scores for females and older patients andmoreover for patients
with myocardial infarction (MI) compared to patients with
angina. A similar distribution was found in a study by Alphin
et al. [16] where patients with heart failure reported the lowest
physical health, followed by patients with MI and then angina.
The impact of a chronic condition onmental health was always
lower than physical health. Meta-analyses or systematic
reviews showed that the SF-36 also correlates with disease-
specific questionnaires like for heart failure [17] and is a pre-
dictor of health status [18] confirming its broad area of appli-
cation [19].
Despite the widespread use of the SF-36 in different
populations, to our knowledge, no international IHD ref-
erence data in patients with angina, MI or ischemic heart
failure are available. As a result, international comparisons
(especially including Eastern European countries) with
data acquired on the basis of either one defined study
protocol or studies by independent researchers are
unavailable. Therefore, the aim of this report is to present
international reference data for the SF-36 (including sub-
analyses on the effect of, e.g., diagnosis, gender and age)
based on a sample of 5508 adult patients with IHD and a
diagnosis of angina, MI or ischemic heart failure living in
one of 22 countries and speaking one of 15 languages.
Methods
Sample
The data analyzed in this study were generated in the
HeartQoL Project where a new HRQL disease-specific
questionnaire for patients with IHD—the HeartQoL
questionnaire—was developed and validated [21, 22].
The HeartQoL Project is an international HRQL survey
conducted between 2002 and 2011, including 6384
patients with documented angina, MI or ischemic heart
failure living in five regions (Eastern, Northern,
Southern and Western European regions and an English-
speaking region) with a total of 22 countries where 15
languages are spoken: Danish, Dutch, English (Aus-
tralia, Canada, Ireland, UK, USA), French, Flemish,
German (Austria, Germany, Switzerland), Hungarian,
Italian, Norwegian, Polish, Portuguese, Russian, Span-
ish (Cuba, Spain), Swedish and Ukrainian. Each of the
sites (N = 67) received local Ethics Committee or
Institutional Review Board approval. Following specific
protocol directions (e.g., guidelines were specified in
each language for identifying crucial disease symptoms,
universal inclusion criteria, workshops on standardized
surveying), participating physician investigators at a
total of 67 sites (hospital cardiology clinics and cardiac
rehabilitation programs) identified eligible patients
when seen at their clinic visit; the nature and purpose of
the study was then explained, and, with written
informed consent, eligible patients were enrolled in the
study.
Eligibility criteria
All HeartQoL Project patients had to be at least 18 years
old, were not currently substance abusers, did not have a
serious psychiatric disorder, were considered by the refer-
ring physician to be able to complete a self-administered
battery of HRQL instruments in the particular language and
had not been hospitalized during the past 6 weeks [21, 22].
Patient physicians reported the primary diagnosis of ang-
ina, MI or ischemic heart failure according the following
criteria:
1. Currently treated for angina (typical chest pain,
Canadian Cardiovascular Society (CCS) class II, III
or IV) with an objective measure of IHD (exercise
testing, echocardiogram, nuclear imaging or angiogra-
phy); or
2. Experienced a documented MI between 1 and
6 months previously, including chest discomfort, elec-
trocardiogram changes indicative of MI and positive
creatine kinase or troponin rise; or
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3. Currently treated for ischemic heart failure (New York
Heart Association (NYHA) class II, III, or IV) with
evidence of left ventricular dysfunction (ejection
fraction \40 % by invasive or noninvasive testing)
and IHD (previous MI, exercise testing, echocardio-
gram, nuclear imaging or angiography). Other under-
lying heart failure diagnoses were excluded.
SF-36 health survey (version 1)
The SF-36 [8] consists of 36 items, each scored in one of
eight scales (Physical Functioning, Role-Physical, Bodily
Pain, General Health, Vitality, Social Functioning, Role-
Emotional, Mental Health) which then form two distinct
higher-ordered clusters—the physical component summary
(PCS) and mental component summary (MCS) measure.
Data from the eight scales are presented as raw values
(0–100). PCS/MCS data are presented as T-scores with a
mean (M) of 50 ± 10 standard deviation (SD), with higher
scores indicating better HRQL. The instrument meets
required psychometric standards [5] and is one of the most
widely used generic HRQL measures in patients with IHD
[12–19]. Reference data on the eight scales and the higher-
ordered PCS/MCS measures are available [7, 8]. The first
SF-36 question ‘‘In general, would you say your health
is…excellent/very good/good/fair/poor?’’ was used to char-
acterize the current health status of the sample (Table 1).
Statistical analyses
Data are presented as M ± SD, lowest and highest SF-36
scores, medians and 25th and 75th percentiles including
Cronbach’s Alpha a as follows; (a) socio-demographic
characteristics (age, gender, education, family status);
(b) clinical characteristics (angina, MI or ischemic heart
failure including the SF-36 question on self-reported
health, disease severity, risk factors); and (c) geographic
regions. Sites were located in Eastern Europe (EE)—
Hungary, Poland, Russia, Ukraine (N = 4 sites); English-
speaking countries (ES)—Australia, Canada, Ireland/UK,
USA (N = 19 sites); Scandinavia (Sc)—Denmark, Nor-
way, Sweden (N = 11 sites); Southern Europe (SE)—Italy,
Spain, Portugal (N = 10); Cuba (N = 1); and Western
Europe (WE)—Austria/Germany/Switzerland, Belgium,
France, Netherlands (N = 22). We combined German
language data from Austria, Germany and Switzerland and
European English language data from Ireland and UK.
Cuban and Spanish patients were originally pooled in the
parent HeartQoL Project to a ‘‘Spanish-speaking group’’
for maximizing variance but, within this analysis, patients
coming from Cuba were examined separately due to
economic and cultural differences. Means are provided for
the PCS and MCS measures and raw values for the eight
SF-36 scales. SPSS 21 was used for all statistical analyses
(descriptive statistics; crosstabs; independent-samples
t tests, uni- and multivariate analyses of variance
(ANOVA; MANOVA) with Bonferroni correction (BC)
investigating group differences; z tests for population
proportions) and effect sizes (partial eta-squared (gp
2) or
Cohen’s d are reported. Incomplete datasets (e.g., missing
values on age, gender or diagnosis, incomplete SF-36 data)
and SF-36 outliers with standardized z-scores in excess of
3.29 [23] were excluded from the total dataset (description
within the limitation section), leading to a cohort of 5508
patients.
Results
Socio-demographic and clinical characteristics
(Table 1)
In this analysis, there were 1836 patients (33.3 %) with
documented angina, 2086 (37.9 %) with a documented MI
and 1586 (28.8 %) with documented ischemic heart failure.
Socio-demographic and clinical characteristics are detailed in
Table 1. Based on the first SF-36 question ‘‘In general, would
you say your health is…?’’, only 1.8 % of the patients rated
their health as ‘‘excellent’’, 47.3 % rated their health as being
either ‘‘very good’’ or ‘‘good’’, 41.5 % rated their health as
‘‘fair’’ and 9.4 % rated their health as ‘‘poor’’. There were
1160 patients from EE (21.1 %), 1231 from ES (22.3 %), 856
from Sc (15.5 %), 793 from SE (14.4 %), 1309 from WE
(23.8 %) and 159 from Cuba (2.9 %).
SF-36 component summary measures: diagnosis,
gender and age (Table 2)
All M ± SD, minimum, maximum, 25th, 50th and 75th
percentile PCS/MCS scores and Cronbach’s Alpha for
diagnosis, gender and age are given in Table 2.
Mean PCS and MCS scores
The mean PCS score in the cohort was 39.8 ± 9.9, more
than one SD below the standardized M of 50, and the mean
MCS score of 47.7 ± 10.6 was within the normal range of
40–60.
Diagnosis
A main effect of diagnosis on mean PCS scores was found
(ANOVA; F(2, 5505) = 274, p\ 0.001, gp
2 = 0.091). Post
hoc analyses using BC indicated that mean PCS scores of




diagnosis, age, gender, family
status, education, self-reported
health, region, risk factors and
disease severity (data missing if
sample sizes do not equal N or
100 % for each group)
Analyzed cohort Angina MI Heart failure
N % N % N % N %
5508 100.0 1836 33.3 2086 37.9 1586 28.8
Gender
Female 1312 23.8 494 26.9 480 23.0 338 21.3
Male 4196 76.2 1342 73.1 1606 77.0 1248 78.7
Age (years – SD) 62.0 ± 11.2 62.6 ± 10.1 59.2 ± 11.2 64.8 ± 11.5
Age category
\51 866 15.7 222 12.1 465 22.3 179 11.3
51–60 1656 30.1 579 31.5 705 33.8 372 23.5
61–70 1676 30.4 608 33.1 562 26.9 506 31.9
[70 1310 23.8 427 23.3 354 17.0 529 33.4
Family status
Single 632 11.5 194 10.6 243 11.6 195 12.3
Married 4145 75.3 1395 74.4 1570 75.3 1180 74.4
Other 667 12.1 216 11.8 254 12.2 197 12.4
Education
\High school 1947 35.3 674 36.7 659 31.6 614 38.7
High school 1708 31.0 587 32.0 654 31.4 467 29.4
[High school 1674 30.4 502 27.3 717 34.4 455 28.7
Self-reported health
Excellent 97 1.8 24 1.3 56 2.7 17 1.1
Very good 562 10.2 162 8.9 308 14.8 92 5.8
Good 2034 37.1 627 34.3 914 44.0 493 31.2
Fair 2276 41.5 818 44.7 689 33.2 769 48.7
Poor 518 9.4 199 10.9 111 5.3 208 13.2
Region
Eastern Europe 1160 21.1 398 21.7 401 19.2 361 22.8
English speaking 1231 22.3 442 24.1 437 20.9 352 22.2
Scandinavia 856 15.5 291 15.8 316 15.1 249 15.7
Southern Europe 793 14.4 262 14.3 308 14.8 223 14.1
Cuba 159 2.9 57 3.1 74 3.5 28 1.8
Western Europe 1309 23.8 386 21.0 550 26.4 373 23.5
Risk factors
Hypertensiona 3066 55.7 1184 64.5 1046 50.1 836 52.7
Diabetesa 1116 20.3 397 21.6 313 15.0 406 25.6
Hypercholesterola 3305 60.0 1234 67.2 1212 58.1 859 54.2
Smoking 818 14.9 241 13.1 346 16.6 231 14.6
BMI (mean ± SD) 27.4 ± 5.0 27.9 ± 4.9 26.9 ± 4.7 27.3 ± 5.1
Physical inactivityb 3693 68.0 1229 67.9 1320 64.0 1144 73.3
Disease severity
CCS II 1235 67.3
CCS III ? IV 543 29.6
NYHA II 912 57.5
NYHA III ? IV 632 39.8
BMI body mass index, CCS Canadian Cardiovascular Society class, MI myocardial infarction, N number of
patients, NYHA New York Heart Association Class, SD standard deviation
a As told by her/his physician
b Active on\3 occasions per week
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Table 2 Physical component summary (PCS) and mental component
summary (MCS) mean scores, standard deviations and Cronbach’s
Alpha by diagnosis, gender and age; grouped by a combination of
gender-diagnosis, age-diagnosis and age-gender-diagnosis (mean PCS
or MCS scores[1 standard deviation below the standardized mean of
50 are bold)
Mean | standard deviation | a Min | max score 25th | 50th | 75th percentile
PCS MCS PCS MCS PCS MCS
Analyzed cohort [N = 5508] 39.8 | 9.9 | 0.90 47.7 | 10.6 | 0.89 10.3 | 66.4 14.0 | 73.7 32.0 | 39.7 | 47.7 39.9 | 48.8 | 56.4
Diagnosis
Angina [N = 1836] 38.5 | 9.5 | 0.89 47.2 | 10.7 | 0.89 11.9 | 66.4 17.2 | 73.1 31.3 | 38.0 | 45.5 39.5 | 48.4 | 56.2
MI [N = 2086] 43.5 | 9.3 | 0.90 47.9 | 10.3 | 0.89 12.6 | 63.8 14.0 | 71.9 36.6 | 44.2 | 50.9 40.6 | 49.2 | 56.4
Heart failure [N = 1586] 36.5 | 9.6 | 0.89 47.9 | 10.7 | 0.88 10.3 | 60.3 17.4 | 73.7 29.3 | 35.3 | 43.7 39.5 | 49.0 | 56.7
Gender and diagnosis
Female [N = 1312] 37.0 | 9.9 | 0.90 45.9 | 10.9 | 0.88 13.7 | 63.1 17.2 | 73.7 29.5 | 36.0 | 44.4 37.5 | 46.7 | 54.7
Angina [N = 494] 35.8 | 9.5 45.7 | 11.2 14.7 | 63.1 17.2 | 68.3 29.2 | 34.3 | 42.5 37.4 | 46.3 | 54.8
MI [N = 480] 40.8 | 9.7 45.6 | 10.5 15.0 | 62.1 21.0 | 67.1 33.1 | 41.1 | 48.5 37.1 | 46.7 | 54.6
Heart failure [N = 338] 33.4 | 9.0 46.6 | 11.1 13.7 | 57.5 17.6 | 73.7 27.1 | 31.9 | 39.3 38.0 | 47.7 | 55.2
Male [N = 4196] 40.6 | 9.7 | 0.90 48.2 | 10.4 | 0.89 10.3 | 66.4 14.0 | 73.1 33.1 | 40.7 | 48.5 40.7 | 49.6 | 56.8
Angina [N = 1342] 39.4 | 9.3 47.8 | 10.4 11.9 | 66.4 17.5 | 73.1 32.4 | 39.1 | 46.4 40.3 | 48.9 | 56.6
MI [N = 1606] 44.2 | 9.0 48.6 | 10.2 12.6 | 63.8 14.0 | 71.9 37.8 | 45.2 | 51.6 41.8 | 50.4 | 56.8
Heart failure [N = 1248] 37.3 | 9.5 48.3 |10.6 10.3 | 60.3 17.4 | 70.8 30.1 | 36.3 | 44.6 39.8 | 49.5 | 57.0
Age and diagnosis
\51 years [N = 866] 42.3 | 9.7 | 0.91 45.9 | 10.9 | 0.90 15.6 | 62.1 16.6 | 68.9 35.1 | 42.4 | 50.5 37.8 | 47.3 | 55.1
Angina [N = 222] 39.5 | 9.8 44.1 | 10.9 18.2 | 60.9 19.3 | 64.7 31.6 | 38.9 | 47.3 36.6 | 45.5 | 53.2
MI [N = 465] 45.2 | 8.9 47.0 | 10.8 15.6 | 62.1 16.6 | 66.9 38.6 | 46.8 | 52.6 39.7 | 48.2 | 55.9
Heart failure [N = 179] 38.4 | 9.4 45.2 | 11.0 19.9 | 58.0 22.2 | 68.9 30.3 | 38.4 | 45.7 36.0 | 45.8 | 53.8
51–60 years [N = 1656] 40.1 | 9.6 | 0.90 46.4 | 10.7 | 0.90 11.9 | 66.4 14.0 | 71.5 32.6 | 40.2 | 47.6 38.5 | 47.0 | 55.6
Angina [N = 579] 38.2 | 9.3 45.2 | 10.9 11.9 | 66.4 17.2 | 67.3 30.9 | 37.5 | 45.2 36.6 | 45.1 | 54.8
MI [N = 705] 43.6 | 8.9 47.3 | 10.3 15.8 | 63.8 14.0 | 71.5 33.2 | 40.0 | 47.0 39.6 | 48.0 | 56.1
Heart failure [N = 372] 36.8 | 9.4 46.5 | 10.8 14.0 | 59.3 17.4 | 70.8 28.2 | 32.6 | 38.1 38.5 | 47.0 | 55.3
61–70 years [N = 1676] 39.7 | 9.9 | 0.90 48.7 | 10.2 | 0.88 11.5 | 62.4 19.1 | 71.9 32.0 | 39.3 | 47.9 41.2 | 50.2 | 57.0
Angina [N = 608] 39.0 | 9.5 48.8 | 10.2 13.5 | 61.5 19.1 | 69.8 32.0 | 38.5 | 46.2 41.9 | 50.4 | 57.0
MI [N = 562] 43.3 | 9.5 48.8 | 10.0 14.1 | 62.4 21.0 | 71.9 35.8 | 44.2 | 51.1 41.7 | 50.5 | 57.0
Heart failure [N = 506] 36.4 | 9.7 48.5 | 10.4 11.5 | 57.9 23.8 | 69.0 29.4 | 35.6 | 44.2 39.8 | 49.8 | 57.0
[70 years [N = 1310] 37.8 | 9.8 | 0.89 49.2 | 10.3 | 0.87 10.3 | 60.3 18.4 | 73.7 30.1 | 37.3 | 45.3 41.9 | 50.4 | 57.8
Angina [N = 427] 37.6 | 9.5 49.4 | 10.1 16.3 | 58.1 21.8 | 73.1 30.3 | 37.3 | 44.6 42.4 | 50.9 | 57.8
MI [N = 354] 41.2 | 9.8 48.8 | 10.0 12.6 | 60.2 18.4 | 66.5 33.3 | 41.9 | 49.1 41.9 | 50.0 | 57.5
Heart failure [N = 529] 35.6 | 9.5 48.5 | 10.4 10.3 | 60.3 20.6 | 73.7 28.6 | 34.3 | 42.5 41.3 | 50.3 | 58.0
Age, gender and diagnosis
\51 years and female [N = 195] 41.0 | 10.3 45.0 | 10.9 15.6 | 62.1 19.6 | 63.8 32.9 | 40.6 | 49.4 37.8 | 47.6 | 53.4
Angina [N = 62] 38.9 | 10.2 43.6 | 11.9 18.1 | 60.9 19.6 | 63.1 30.6 | 37.4 | 46.8 36.6 | 46.4 | 53.2
MI [N = 96] 43.6 | 10.0 45.0 | 10.3 15.6 | 62.1 21.3 | 62.7 37.3 | 44.5 | 52.1 40.7 | 46.8 | 53.5
Heart failure [N = 37] 37.5 | 9.3 47.6 | 10.4 20.1 | 55.0 24.6 | 63.8 29.7 | 36.4 | 46.1 35.2 | 50.4 | 53.7
\51 years and male [N = 671] 42.7 | 9.5 46.1 | 10.9 16.2 | 62.1 16.6 | 68.9 35.7 | 42.8 | 50.6 37.8 | 47.3 | 55.5
Angina [N = 160] 39.7 | 9.7 44.3 | 10.5 21.1 | 58.8 20.1 | 64.7 31.9 | 39.1 | 47.6 36.5 | 44.6 | 52.9
MI [N = 369] 45.6 | 8.5 47.5 | 10.9 16.2 | 62.1 16.6 | 66.9 39.3 | 46.9 | 52.8 40.7 | 50.0 | 56.2
Heart failure [N = 142] 38.6 | 9.4 45.2 | 11.1 19.9 | 58.0 22.2 | 68.9 30.5 | 39.3 | 45.7 35.2 | 44.8 | 53.8
51–60 years and female [N = 342] 37.2 | 9.6 43.6 | 11.2 14.7 | 63.1 17.2 | 70.1 30.1 | 35.2 | 44.3 34.8 | 42.8 | 52.3
Angina [N = 139] 35.8 | 9.5 42.7 | 11.1 14.7 | 63.1 17.2 | 65.8 30.6 | 37.4 | 46.8 37.8 | 46.3 | 55.5
MI [N = 135] 40.6 | 9.3 45.0 | 10.6 15.8 | 59.6 22.6 | 65.0 37.3 | 44.5 | 52.1 40.3 | 49.0 | 56.4
Heart failure [N = 68] 33.5 | 8.0 42.9 | 12.4 19.3 | 56.3 17.6 | 70.1 29.7 | 36.4 | 46.1 39.4 | 47.9 | 55.4
51–60 years and male [N = 1314] 40.9 | 9.5 47.1 | 10.4 11.9 | 66.4 14.0 | 71.5 33.7 | 41.1 | 48.1 39.4 | 47.7 | 55.9
Angina [N = 440] 38.9 | 9.2 46.0 | 10.7 11.9 | 66.4 17.5 | 67.3 32.0 | 38.7 | 45.5 37.8 | 46.3 | 55.5
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patients with MI were significantly higher than in patients
with either angina (p\ 0.001, d = 0.53) or ischemic heart
failure (p\ 0.001; d = 0.74) who also had a significantly
lower mean PCS score compared to patients with angina
(p\ 0.001, d = 0.21). All MCS scores were within the
normal range and did not differ statistically (ANOVA; F(2,
5505) = 2.5, p = 0.083, gp
2 = 0.001).
Gender
An independent-samples t test indicated that mean PCS
scores were significantly lower for women (37.0 ± 9.9)
than for men (40.6 ± 9.7; t(5506) = 11.7, p\ 0.001,
d = 0.37). Although mean MCS scores were in the normal
range for both genders, female patients reported lower
scores (45.9 ± 10.9) than male patients (48.2 ± 10.4;
t(2101) = 6.9, p\ 0.001, d = 0.22).
Age
A main effect of age on mean PCS scores was found
(ANOVA; F(3, 5504) = 38.4, p\ 0.001, gp
2 = 0.020).
According to post hoc analyses, patients\51 years repor-
ted significantly higher mean PCS scores compared to all
other age groups (BC, all p\ 0.001; vs. 51–60 years
d = 0.22; vs. 61–70 years d = 0.27; vs.[ 70 years
d = 0.46). Patients[70 years had the lowest mean PCS
scores (BC, all p\ 0.001; vs. 51–60 years d = 0.24; vs.
61–70 years d = 0.19). A main effect of age was also
found on mean MCS scores (ANOVA; F(3, 5504) = 31.6,
p\ 0.001, gp
2 = 0.017) with patients\51 and 51–60 years
reporting significantly lower MCS scores than both older
aged groups (BC, all p\ 0.001; \51 vs. 61–70 years
d = 0.27 and vs.[ 70 years d = 0.32; 51–60 vs.
61–70 years d = 0.22 and vs.[70 years: d = 0.27).
Interaction effects
Sub-analyses investigating interaction effects of diagno-
sis 9 gender, diagnosis 9 age, gender 9 age, diagno-
sis 9 gender 9 age showed no significant results for either
PCS or MCS scale, except for gender 9 age on PCS
(MANOVA; F(3,5500) = 4.19, p = 0.006, gp
2 = 0.002)
and diagnosis 9 age on MCS (MANOVA;
F(6,5496) = 2.71, p = 0.012, gp
2 = 0.003). However, the
effect sizes for both are negligible.
SF-36 component summary measures: region
and country within region (Table 3)
All M ± SD, minimum, maximum, 25th, 50th and 75th
percentile PCS/MCS scores and Cronbach’s Alpha for each
region and country are given in Table 3. All means were
tested for possible influences of the different data
Table 2 continued
Mean | standard deviation | a Min | max score 25th | 50th | 75th percentile
PCS MCS PCS MCS PCS MCS
MI [N = 570] 44.3 | 8.7 47.8 | 10.2 19.4 | 63.8 14.0 | 71.5 38.3 | 44.9 | 50.9 40.3 | 49.0 | 56.4
Heart failure [N = 304] 37.5 | 9.5 47.3 | 10.3 14.0 | 59.3 17.4 | 70.8 30.2 | 36.3 | 54.8 39.4 | 47.9 | 55.4
61–70 years and female [N = 421] 36.6 | 9.8 46.0 | 11.0 13.7 | 57.8 20.3 | 67.1 29.3 | 35.2 | 44.2 37.4 | 46.4 | 55.2
Angina [N = 174] 36.3 | 9.3 46.7 | 11.2 16.7 | 57.8 20.3 | 66.0 29.4 | 34.5 | 43.2 38.3 | 47.0 | 56.9
MI [N = 133] 40.0 | 9.6 44.9 | 10.8 15.0 | 57.4 21.0 | 67.1 31.2 | 40.9 | 47.6 36.7 | 45.7 | 53.7
Heart failure [N = 114] 33.2 | 9.5 46.3 | 10.7 13.7 | 57.5 24.0 | 66.0 26.4 | 31.2 | 40.2 37.8 | 47.2 | 54.4
61–70 years and male [N = 1255] 40.7 | 9.8 49.6 | 9.7 11.5 | 62.4 19.1 | 71.9 33.4 | 40.5 | 48.9 43.3 | 51.2 | 57.4
Angina [N = 434] 40.1 | 9.3 49.6 | 9.6 13.5 | 61.5 19.1 | 69.8 33.9 | 39.5 | 47.4 44.0 | 51.2 | 57.0
MI [N = 429] 44.3 | 9.3 50.0 | 9.5 14.1 | 62.4 21.6 | 71.9 37.5 | 46.0 | 51.8 44.0 | 52.0 | 57.7
Heart failure [N = 392] 37.4 | 9.5 49.1 | 10.2 11.5 | 57.9 23.8 | 69.0 30.4 | 36.6 | 44.8 40.2 | 50.4 | 57.5
[70 years and female [N = 354] 35.2 | 9.6 48.4 | 10.2 15.7 | 60.2 20.4 | 73.7 27.7 | 33.7 | 42.3 41.6 | 49.2 | 56.7
Angina [N = 119] 33.6 | 8.9 48.9 | 10.1 16.3 | 56.9 23.4 | 68.3 26.4 | 33.0 | 39.8 42.2 | 49.6 | 56.9
MI [N = 116] 39.8 | 9.7 47.6 | 10.1 20.5 | 60.2 23.0 | 66.5 31.6 | 40.9 | 47.9 40.1 | 47.9 | 56.7
Heart failure [N = 119] 32.2 | 8.5 48.6 | 10.4 15.7 | 55.4 20.4 | 73.7 26.6 | 31.1 | 37.6 41.6 | 49.7 | 57.1
[70 years and male [N = 956] 38.7 | 9.8 49.5 | 10.3 10.3 | 60.3 18.4 | 73.1 31.4 | 38.4 | 46.2 42.0 | 50.8 | 57.9
Angina [N = 308] 39.1 | 9.2 49.7 | 10.2 18.8 | 58.1 21.8 | 73.1 32.0 | 38.9 | 45.8 42.6 | 51.3 | 57.8
MI [N = 238] 41.9 | 9.8 49.4 | 10.0 12.6 | 59.9 18.4 | 66.2 34.2 | 42.5 | 50.0 42.7 | 50.9 | 58.0
Heart failure [N = 410] 36.6 | 9.6 49.5 | 10.6 10.3 | 60.3 23.6 | 68.5 29.7 | 35.2 | 43.6 41.1 | 50.1 | 58.4
MI myocardial infarction, N number of patients
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collecting sites, and all differences were less than the
minimal important difference.
PCS scores
By region, the mean PCS score was more than one SD below
the standardized M = 50 in Eastern Europe and the English-
speaking region. The mean PCS score in EE was 35.9 ± 8.5,
with each country in this region scoring more than one SD
below M = 50. In the ES region, the mean PCS score was
39.7 ± 10.9, with only Canada within the normal range. In
Sc, the mean PCS score was 40.5 ± 10.1; only Norway
scored more than one SD below M = 50. In SE and WE, the
mean PCS scores (40.9 ± 9.2; 42.4 ± 9.3) in all countries
were within the normal range. In Cuba, the mean PCS score
was 38.4 ± 8.6, significantly different from Spain
(40.6 ± 10.0; t(372) = 2.41, p = 0.016, d = 0.37).
A main effect of the region (ANOVA; F(4, 5503) = 73.6,
p\0.001, gp
2 = 0.051) and the country (ANOVA; F(17,
5490) = 23.8, p\0.001, gp
2 = 0.069) was found on mean
PCS scores. Post hoc analyses indicated that patients in EE
had significantly lower mean PCS scores than in each other
region (BC, all p\0.001; vs. ES, d = 0.39; vs. Sc,
d = 0.49; vs. SE, d = 0.56; vs. WE, d = 0.73) and patients
in WE had the highest mean PCS score when compared to
each other region (BC, all p\0.01; vs. ES, d = 0.27; vs. Sc,
d = 0.20; vs. SE, d = 0.16). Except Hungary and Ukraine,
the lowest PCS score in Russia was significantly lower than in
all other countries (p\0.001); Austria/Germany/Switzer-
land’s, the Netherlands’ and Belgium’s PCS scores were
significantly higher than those reported in Russia, Hungary,
Ukraine, Australia, Poland, Ireland/UK, Norway and the USA
(all p\0.001).
MCS scores
By region, each mean MCS score was within one SD± the
standardized M = 50, ranging from 44.7 ± 10.0 in EE to
Table 3 Physical component summary (PCS) and mental component summary (MCS) mean scores, standard deviations and Cronbach’s Alpha
grouped by region and countries (mean PCS or MCS scores[1 standard deviation below the standardized mean of 50 are bold)
Mean | standard deviation | a Min | max score 25th | 50th | 75th percentile
PCS MCS PCS MCS PCS MCS
Eastern Europe [N = 1160] 35.9 | 8.5 | 0.87 44.7 | 10.0 | 0.88 14.0 | 61.4 17.6 | 70.8 29.5 | 34.4 | 41.7 37.0 | 45.1 | 52.5
Hungary [N = 263] 35.5 | 8.6 | 0.89 45.4 | 11.8 | 0.90 14.0 | 57.7 19.7 | 70.8 29.4 | 34.7 | 41.4 35.8 | 45.9 | 55.4
Poland [N = 314] 38.1 | 10.1 | 0.88 46.3 | 9.9 | 0.88 18.8 | 60.5 21.1 | 65.6 30.0 | 36.9 | 45.7 39.5 | 47.4 | 54.0
Russia [N = 304] 34.1 | 6.9 | 0.86 43.3 | 9.6 | 0.89 18.3 | 59.3 20.6 | 63.2 29.0 | 33.1 | 38.2 35.9 | 42.9 | 50.7
Ukraine [N = 279] 35.6 | 7.6 | 0.86 43.8 | 8.5 | 0.87 18.2 | 61.4 17.6 | 63.9 29.9 | 34.3 | 41.9 37.5 | 43.7 | 50.5
English speaking [N = 1231] 39.7 | 10.9 | 0.92 49.8 | 10.1 | 0.87 13.0 | 63.8 17.9 | 73.7 30.5 | 40.0 | 48.8 42.3 | 51.4 | 58.2
Australia [N = 220] 38.1 | 11.2 | 0.90 48.1 | 10.8 | 0.87 16.2 | 63.8 22.6 | 66.2 28.1 | 35.5 | 48.7 39.6 | 49.4 | 57.8
Canada [N = 328] 42.4 | 10.5 | 0.91 51.0 | 9.4 | 0.87 13.0 | 61.6 21.6 | 67.2 35.9 | 44.0 | 50.6 45.3 | 53.5 | 58.5
Ireland/UK [N = 266] 38.4 | 11.0 | 0.92 50.6 | 9.8 | 0.86 14.1 | 62.4 17.9 | 66.9 29.5 | 38.5 | 47.4 44.8 | 52.2 | 58.2
USA [N = 417] 39.2 | 10.6 | 0.92 49.3 | 10.3 | 0.88 14.9 | 61.6 19.6 | 73.7 30.3 | 38.7 | 48.0 41.5 | 50.9 | 57.9
Scandinavia [N = 856] 40.5 | 10.1 | 0.91 49.6 | 10.0 | 0.89 10.9 | 60.2 21.6 | 73.1 32.6 | 40.8 | 48.8 42.4 | 50.7 | 57.7
Denmark [N = 277] 42.2 | 9.7 | 0.92 50.3 | 9.8 | 0.90 20.2 | 58.1 21.6 | 73.1 34.3 | 43.0 | 50.8 43.7 | 51.9 | 57.9
Norway [N = 294] 38.4 | 10.2 | 0.90 49.6 | 9.9 | 0.88 10.9 | 59.3 23.8 | 70.5 30.5 | 39.2 | 45.7 42.3 | 50.7 | 57.6
Sweden [N = 285] 40.9 | 9.9 | 0.91 49.0 | 10.3 | 0.88 12.6 | 60.2 24.2 | 70.5 33.0 | 40.9 | 48.9 41.2 | 50.3 | 57.8
Southern Europe [N = 793] 40.9 | 9.2 | 0.88 47.9 | 10.5 | 0.88 10.3 | 61.7 17.4 | 68.9 33.9 | 41.1 | 48.6 40.9 | 49.4 | 56.7
Italy [N = 258] 42.0 | 9.2 | 0.87 46.9 | 9.8 | 0.86 19.2 | 59.6 24.2 | 68.9 35.0 | 42.8 | 49.8 39.4 | 47.9 | 54.4
Portugal [N = 277] 40.2 | 8.8 | 0.88 45.1 | 11.0 | 0.90 19.5 | 61.7 17.4 | 65.2 33.4 | 39.7 | 47.3 37.6 | 45.4 | 54.8
Spain [N = 258] 40.6 | 10.0 | 0.90 51.9 | 9.5 | 0.88 10.3 | 60.3 20.1 | 66.7 32.7 | 41.1 | 48.5 46.4 | 54.0 | 59.1
Cuba [N = 159] 38.4 | 8.6 | 0.85 49.2 | 11.2 | 0.85 19.1 | 55.8 18.4 | 71.5 33.0 | 38.0 | 45.3 43.5 | 49.8 | 57.5
Western Europe [N = 1309] 42.4 | 9.3 | 0.90 46.7 | 11.0 | 0.91 11.9 | 66.4 14.0 | 70.5 35.4 | 42.7 | 49.9 38.6 | 47.8 | 56.0
Aust/Ger/Swiz [N = 329] 42.8 | 9.1 | 0.89 46.6 | 10.8 | 0.92 17.9 | 62.1 21.0 | 65.8 35.6 | 43.1 | 50.2 38.7 | 48.0 | 56.3
Belgium [N = 304] 42.8 | 9.7 | 0.90 50.1 | 10.0 | 0.89 19.3 | 63.1 16.6 | 68.1 35.4 | 43.3 | 50.8 43.7 | 52.1 | 58.1
France [N = 345] 41.2 | 8.0 | 0.87 41.3 |10.6 | 0.89 22.2 | 59.6 14.0 | 67.2 35.5 | 41.0 | 47.3 33.0 | 41.1 | 49.6
Netherlands [N = 331] 42.8 | 10.2 | 0.92 49.4 | 10.2 | 0.91 11.9 | 66.4 22.0 | 70.5 34.6 | 44.0 | 50.9 43.2 | 51.5 | 57.3
Aust/Ger/Swiz Austria/Germany/Switzerland, N number of patients, UK United Kingdom, USA United States of America
Qual Life Res (2016) 25:2787–2798 2793
123
49.8 ± 10.1 in the ES region. A main effect of region
(ANOVA; F(4, 5503) = 47.5, p\ 0.001, gp
2 = 0.033) and
country (ANOVA; F(17, 5490) = 26.2, p\ 0.001,
gp
2 = 0.075) was found on mean MCS scores. Post hoc
analyses indicated that patients in EE had significantly
lower mean MCS scores than in each other region although
they were all within the normal range (BC, all p\ 0.001;
vs. ES d = 0.50; vs. Sc d = 0.49; vs. SE d = 0.31; vs. WE
d = 0.19). Patients in the ES region had higher mean MCS
scores than SE and WE patients (BC, all p\ 0.01; vs. SE
d = 0.18; vs. WE d = 0.29), and so did patients from Sc
(BC, all p\ 0.02; vs. SE d = 0.17; vs. WE d = 0.28).
France had the significantly lowest mean MCS score
compared to all other countries (p\ 0.001), except for
Russia and Ukraine. Patients in Spain, Canada and Ireland/
UK had significantly the highest mean MCS scores when
compared to patients from France, Russia, Ukraine, Por-
tugal, Hungary, Austria/Germany/Switzerland and Italy (all
p\ 0.001).
SF-36 scales: age, gender, diagnosis, region
and country (Table 4)
The raw values of the eight scales give more detailed
information than PCS and MCS values and are presented in
detail in Table 4. As further country-specific reference data
would be helpful, supplementary material for each country
presenting reference values by diagnosis, age and gender
separately are available [online resource 1].
Discussion
The key to the interpretation of HRQL as an outcome is
having reference values as these are useful for users of an
instrument who wish to place their results in an appropriate
context by comparing their scores to a reference group [6].
Without reference values, it is difficult for the user, whe-
ther clinicians, researchers, or policy makers, to assess the
meaning of the comparative or relative scores. This is the
first dedicated study representing generic HRQL SF-36
international IHD reference values allowing comparisons
across angina, MI and ischemic heart failure as well as
across 22 countries in one publication. The pattern of all
HRQL differences observed in this report is similar to
findings of other studies using the SF-36 [15, 16] or SF-12
[20]. The SF-36 scores reported here by 5508 patients
substantiate findings from other studies (e.g., EuroAspire)
[20], therefore contributing to the establishment of rela-
tionships between HRQL and variables such as diagnosis,
age, gender or region.
The mean PCS score in the analyzed cohort with IHD
was below the normal range of 40–60, whereas the mean
MCS score was within this range. Diagnosis exerted an
influence on physical health with patients with MI always
reporting the highest mean PCS scores. However, patients
with angina and ischemic heart failure were more than one
SD below the standardized PCS mean score. On the other
hand, cardiac diagnosis had no effect on the mean MCS
scores which were all within the normal range. These
results indicate that angina and especially ischemic heart
failure have a greater impact on physical health than MI.
This might be due to their different subsequent physical
limitations and chronicity. Furthermore, cardiac diseases
apparently have a stronger influence on physical than on
mental health. Females reported worse physical and mental
health than males. This maybe indicates more subjective
perceived physical and mental burden in women. Worse
physical health was also reported by older patients (espe-
cially in those [70 years), whereas younger patients
(especially in those \51 years) had lower mean MCS
scores in comparison. These results may lead to the
assumption that younger patients are fitter and therefore
can handle physical strain due to a cardiac disease better
than older patients. In contrast, older patients perceive less
mental stress because of more coping strategies available
or the feeling of ‘‘normality’’ when they are confronted
with a cardiac disease at a greater age. Finally, patients
from EE had significantly lower physical and mental health
scores than patients from all other regions. These PCS and
MCS results, with patients from EE are reporting worse
HRQL than patients from the other regions, are consistent
with the well-recognized East–West health divide [13, 24].
The well-known East–West Europe health divide
between Eastern Europe, i.e., the formerly communist
countries of Central and Eastern Europe and the former
Soviet Union [24, 25], and Western Europe reflects major
differences in health policy, access to and quality of health
care, health care funding, and certain health risks and their
impact on health outcomes such as life expectancy, mor-
bidity and mortality. The East–West Europe health divide
was confirmed for HRQL as a patient-reported outcome
measure in this report. The combined effects of economic
growth, improved health care and successful health policies
(e.g., tobacco and alcohol control, food policy, road traffic
safety) across Western Europe have resulted in a higher life
expectancy, lower mortality and morbidity and healthier
populations [20, 24]. In contrast, economic and political
problems in many Eastern European countries have fre-
quently led to a failure to implement effective health
policies with concomitant lower life expectancies, higher
mortality and morbidity and less healthy populations [26].
However, inequities in health, health care and health care
policies also exist within and between neighboring coun-
tries in Western Europe [24, 27, 28] and remarkable HRQL
differences between neighboring countries have been noted
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in this analysis indicating further challenges to health,
well-being and health care in Western Europe [20].
The generic SF-36 is useful when comparing various
populations with a healthy cohort. The SF-36 PCS and
MCS measures, with a standardized mean of 50 ± 10, are
derived from the general ‘‘healthy’’ US population [8].
There are SF-36 norms by IHD diagnosis, i.e., angina, MI
and heart failure, in the German [7] and US [8] population
Table 4 SF-36 scales (raw values 0–100) grouped by diagnosis, gender, age and region including countries
Mean | standard deviation
Scales in the physical component summary
measure (PCS)
Scales in the mental component summary
measure (MCS)
PFI ROLPH PAIN GHP VITAL SOCIAL ROLEM MHI
Diagnosis
Angina [N = 1836] 62.3 | 23.8 39.2 | 40.9 56.8 | 24.6 50.1 | 20.1 51.5 | 20.2 73.1 | 23.7 57.3 | 42.9 67.5 | 19.1
MI [N = 2086] 73.4 | 22.3 43.5 | 41.9 71.7 | 25.0 58.6 | 20.2 57.9 | 20.6 76.9 | 23.1 61.0 | 42.3 71.0 | 18.8
Heart failure [N = 1586] 52.9 | 24.6 32.9 | 40.1 64.1 | 26.1 46.3 | 19.2 49.7 | 20.5 71.5 | 24.2 56.3 | 43.4 68.7 | 19.6
Gender
Female [N = 1312] 53.7 | 25.1 32.9 | 40.0 59.1 | 26.4 48.6 | 19.9 47.9 | 20.4 70.5 | 24.6 50.6 | 43.4 64.7 | 19.9
Male [N = 4196] 67.0 | 24.0 41.0 | 41.5 66.2 | 25.6 53.4 | 25.1 55.1 | 20.5 75.2 | 23.3 60.8 | 42.4 70.6 | 18.7
Age
\51 years [N = 866] 72.2 | 23.4 41.0 | 41.0 67.2 | 25.9 52.5 | 20.8 54.0 | 20.7 73.7 | 23.8 58.7 | 43.0 66.0 | 19.7
51–60 years [N = 1656] 66.2 | 23.7 37.6 | 40.6 62.4 | 25.9 51.6 | 20.7 52.9 | 20.6 72.7 | 23.7 55.2 | 42.6 67.1 | 19.3
61–70 years [N = 1676] 63.6 | 24.9 40.7 | 42.2 65.0 | 25.6 52.7 | 20.4 54.0 | 21.0 75.6 | 23.6 61.7 | 42.5 70.6 | 18.5
[70 years [N = 1310] 55.5 | 25.0 37.5 | 41.1 64.9 | 26.3 52.2 | 20.5 52.8 | 20.6 74.1 | 23.8 58.1 | 43.3 72.0 | 18.8
Eastern Europe
Hungary [N = 263] 57.9 | 22.8 23.7 | 33.6 53.3 | 26.2 39.4 | 17.5 52.0 | 22.2 70.3 | 25.4 37.5 | 40.9 66.8 | 21.4
Poland [N = 314] 57.8 | 24.8 39.0 | 44.5 57.2 | 28.1 49.0 | 16.7 53.3 | 18.2 69.7 | 25.6 62.2 | 43.5 60.6 | 17.8
Russia [N = 304] 50.3 | 21.5 22.3 | 33.9 49.2 | 19.4 41.0 | 12.0 45.8 | 17.6 61.4 | 22.6 46.1 | 42.3 57.7 | 15.9
Ukraine [N = 279] 53.6 | 21.6 28.9 | 37.8 52.5 | 21.8 40.5 | 13.4 48.7 | 18.1 63.9 | 20.2 41.5 | 40.3 62.2 | 15.4
English speaking
Australia [N = 220] 57.0 | 28.7 36.6 | 42.6 64.3 | 26.6 53.4 | 22.4 48.5 | 21.9 71.4 | 25.8 55.2 | 44.9 72.7 | 17.9
Canada [N = 328] 71.9 | 23.3 46.8 | 40.7 72.3 | 22.8 59.8 | 21.7 56.1 | 20.3 80.5 | 21.7 70.6 | 39.2 76.9 | 15.4
Ireland/UK [N = 266] 59.0 | 26.8 40.5 | 40.1 68.2 | 26.5 53.2 | 23.1 51.6 | 21.8 74.8 | 23.9 68.4 | 39.5 74.6 | 17.6
USA [N = 417] 58.8 | 27.4 45.0 | 42.7 64.4 | 25.0 54.7 | 22.2 52.8 | 20.4 76.0 | 23.8 59.4 | 44.1 73.1 | 17.9
Scandinavia
Denmark [N = 277] 69.3 | 25.6 45.4 | 41.8 72.4 | 23.4 57.2 | 20.9 56.7 | 23.3 85.2 | 20.4 61.2 | 38.7 75.4 | 18.5
Norway [N = 294] 67.2 | 24.7 26.7 | 37.3 61.6 | 27.7 56.7 | 22.4 49.6 | 20.3 77.0 | 22.5 57.0 | 42.5 76.5 | 16.7
Sweden [N = 285] 64.8 | 23.0 42.6 | 40.0 67.8 | 25.5 56.9 | 21.0 54.2 | 21.0 78,7 | 21.9 56.9 | 41.9 73.8 | 17.7
Southern Europe
Italy [N = 258] 66.3 | 24.4 44.4 | 41.7 70.3 | 26.5 53.3 | 20.0 57.7 | 19.1 72.9 | 22.6 57.9 | 42.7 67.7 | 17.1
Portugal [N = 277] 59.1 | 24.2 46.1 | 41.9 65.7 | 26.0 46.4 | 17.9 51.4 | 20.9 74.1 | 23.4 53.1 | 41.4 62.4 | 22.1
Spain [N = 258] 69.6 | 20.8 51.6 | 43.0 67.5 | 25.4 51.2 | 21.6 56.8 | 22.7 81.9 | 21.7 81.9 | 35.7 72.7 | 18.4
Cuba [N = 159] 66.9 | 20.3 23.3 | 35.7 63.3 | 26.3 52.8 | 16.5 61.1 | 23.7 70.7 | 29.0 81.1 | 34.3 61.0 | 22.6
Western Europe
Aut/Ger/Swiz [N = 329] 70.3 | 23.4 44.6 | 42.1 68.8 | 28.1 56.7 | 17.9 52.8 | 20.7 77.8 | 23.3 59.1 | 43.6 67.6 | 19.4
Belgium [N = 304] 70.5 | 24.5 48.5 | 42.0 71.7 | 22.5 56.8 | 20.3 62.9 | 18.3 79.5 | 20.4 65.5 | 40.6 73.2 | 17.7
France [N = 345] 71.4 | 20.9 27.6 | 36.8 58.1 | 22.5 52.7 | 18.9 46.7 | 17.5 65.6 | 22.6 37.5 | 41.8 62.4 | 19.4
Netherlands [N = 331] 68.8 | 25.3 48.3 | 42.0 76.2 | 23.4 56.9 | 21.8 58.9 | 19.4 74.8 | 21.3 68.3 | 41.1 73.3 | 18.0
Scales in the PCS: PFI, Physical Functioning; ROLPH, Role-Physical; PAIN, Bodily Pain; GHP, General Health
Scales in the MCS: VITAL, Vitality; SOCIAL, Social Functioning; ROLEM, Role-Emotional; MHI, Mental Health
Aust/Ger/Swiz Austria/Germany/Switzerland, N number of patients, UK United Kingdom, USA United States of America
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substantiating the findings in this study of highest scores in
patients with MI, followed by patients with angina, and the
lowest scores in patients with heart failure. Furthermore, in
the German [7] and US [8] general populations, females
reported worse PCS and MCS scores than males and
younger patients reported better PCS and worse MCS
scores older patients. This analysis revealed similar results
within an IHD population. Moreover, there are also PCS
and MCS norms broken down into their components for the
eight SF-36 scales by diagnosis (heart disease in total, MI
and heart failure), age and gender in the US population [8].
The reference values generated in the present study
demonstrated that all PCS scores, but none of the MCS
scores, were more than one SD lower than the general
‘‘healthy’’ US population norms in patients with angina and
heart failure.However, the SF-36 does not quantify symptom
burden or functional limitations specific to IHD and is less
sensitive to clinical change, either over time or after a ther-
apeutic intervention, and its clinical interpretation is more
difficult than with a disease-specific instrument [6] such as
either the MacNew [29] or the HeartQoL [21, 22]. Further-
more, when the SF-36 scales are summated and transformed
to the higher-order PCS and MCS measures, the formula
always includes the means, the SDs and the regression
coefficients from the general American population (‘‘US
weights’’). This needs to be considered when interpreting
these or other SF-36 data in countries other than the USA as,
when interpreting SF-36 data across different groups (e.g.,
gender, ethnicity, language), problems may occur because
people belonging to different groups may have a different
probability of giving a certain response on a questionnaire
[30]. By generating new IHD-specific reference values in the
future, where a standardized mean of 50 ± 10 would rep-
resent the ‘‘average IHD-patient,’’ these specific SF-36 ref-
erence data could be used for comparing scores within an
IHD population more precisely.
Therefore, analyses of measurement invariance or dif-
ferential item functioning can be conducted to provide an
indication of unexpected behavior of items on a test and
giving information on which items may be revised, e.g.,
exclusion, rephrasing, new translation. There is apparently a
valid assumption based on the vast literature that the SF-36 at
least does measure the same construct across different cul-
tures (IQOLA-Project) [31–33]. Moreover, the Bjorner et al.
DIF-study [26] showed that the use of homogenous reduced
scales instead of the full SF-36 scales (containing items with
DIF) did not change conclusions about the existence of a
cross-national difference, at least not between the general
populations in the USA and Denmark. These data can lead to
the assumption that the SF-36 is also robust when locating
items with DIF regarding the ‘‘higher-ordered’’ results
(scales, PCS/MCS) in other populations. But as the study of
Bjorner et al. [26] is unique with results suggesting that
cross-language DIF may be a frequent problem in ques-
tionnaire translations, some consequences occur. Therefore,
validations of translated instruments are needed every time a
questionnaire is presented in a new language and interpre-
tations of cross-national comparison data need to be used
with caution since the interpretation of questions and the use
of response categories may vary between countries.
Limitations
The data are based on convenience samples. This needs to
be considered when referring to these results. For example,
only patients with ischemic heart failure (left ventricular
dysfunction\40 % and IHD) were included, whereas other
heart failure diagnoses were excluded (e.g., preserved
ejection fraction or diastolic heart failure, right heart fail-
ure). Furthermore disease severity, also influencing physi-
cal and mental health, varied across regions in this sample.
The highest proportion of patients with severe angina (CCS
III ? IV) was found in the ES region (36 %) and the
lowest in Sc (20 %). The highest proportion of patients
with severe ischemic heart failure (NYHA III ? IV) was
found in EE (47 %) and the lowest in Sc (28 %).
The 876 excluded participants were more likely to be
female, older, less likely to be married and higher edu-
cated. They reported worse health status (single SF-36
question ‘‘In general, would you say your health is…ex-
cellent/very good/good/fair/poor?’’), came more often from
ES countries, Sc and SE and less often from EE and WE,
were less likely to have hypercholesterolemia but more
likely to be diabetic and physical inactive. Excluding these
patients because of incomplete data or being outliers could
have influenced the presented reference values.
Conclusions
In 5508 patients with angina, MI and ischemic heart failure,
the diagnosis exerted a significant influence on the percep-
tion of physical health with the highest mean SF-36 PCS
scores reported by patients with MI and the poorest scores
reported by patients with heart failure.Worse physical health
was also reported by females, older patients (especially those
[70 years) and patients from EE. The cardiac diagnosis had
no effect on the mean MCS scores which were all within the
normal range; however, females, younger patients (espe-
cially those\51 years) and EE patients reported the lowest
mean MCS scores. Clinicians, researchers, health profes-
sionals and health-policy makers can use these SF-36 ref-
erence values for patients with IHD as an indication of how
an individual patient, or a group of patients, compares to
patients of the same sex, age and diagnosis as well as to
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patients with IHD in a specific country. Important health
challenges that need to be addressed remain in both Eastern
andWestern Europe countries concerning unresolved issues
in health-policy-making and rising health inequalities
between and within countries.
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